Top

Published in:

01-04-2020 | Metastasis | Review

KIBRA Team Up with Partners to Promote Breast Cancer Metastasis

Authors: Garima Singh, Sarthak Mishra, Harish Chander

Published in: Pathology & Oncology Research | Issue 2/2020

Abstract

Among women, breast cancer is the most frequently diagnosed cancer. Most of the breast cancers represent metastasis to distant organs at the time of diagnosis and accounts for the majority of deaths. Metastasis is characterized by many genetic aberrations including mutations, overexpression of oncogenes etc. KIBRA (KIdney/BRAin protein), a scaffolding protein is recently described as an important player in the process of invasion and metastasis. The Kidney/BRAin protein through its different domains interacts with various proteins to couple cytoskeleton arrangement, cell polarity and migration. N terminal and C terminal of the protein contains the WW, Internal C₂ & putative class III PDZ domain that interacts with DDR1, DLC1 & PKCζ. These protein-protein interactions equip the breast cancer cells to invade and metastasize. Here, we discuss a comprehensive knowledge about the KIBRA protein, its domains and the interacting partners involved in metastasis of breast cancer.

Friedenreich CM (2011) Physical activity and breast Cancer: review of the epidemiologic evidence and biologic mechanisms. In: Senn H-J, Otto F (eds) Clinical Cancer prevention. Springer Berlin Heidelberg, Berlin, pp 125–139

Zhang X, Liu X, Luo J, Xiao W, Ye X, Chen M, Li Y, Zhang GJ (2016) Notch3 inhibits epithelial–mesenchymal transition by activating Kibra-mediated hippo/YAP signaling in breast cancer epithelial cells. Oncogenesis 5(11):e269. https://doi.org/10.1038/oncsis.2016.67 PubMedPubMedCentral

Kang Y, Massagué J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. [Short Survey]. Cell 118(3):277–279. https://doi.org/10.1016/j.cell.2004.07.011 PubMed

Thiery JP, Morgan M (2004) Breast cancer progression with a twist. Nat Med 10:777–778. https://doi.org/10.1038/nm0804-777 PubMed

Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial–mesenchymal transitions. [review article]. Nat Rev Mol Cell Biol 7:131. https://doi.org/10.1038/nrm1835 PubMed

Ahmad A, Sarkar SH, Bitar B, Ali S, Aboukameel A, Sethi S, Li Y, Bao B, Kong D, Banerjee S, Padhye SB, Sarkar FH (2012) Garcinol Regulates EMT and Wnt Signaling Pathways In Vitro and In Vivo, Leading to Anticancer Activity against Breast Cancer Cells. Mol Cancer Ther 11(10):2193–2201. https://doi.org/10.1158/1535-7163.mct-12-0232-t PubMed

Debies MT, Gestl SA, Mathers JL, Mikse OR, Leonard TL, Moody SE, Chodosh LA, Cardiff RD, Gunther EJ (2008) Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19(Arf)/p53 pathway lesions but not p16(Ink4a) loss. J Clin Invest 118(1):51–63. https://doi.org/10.1172/JCI33320 PubMed

Li Y, Wicha MS, Schwartz SJ, Sun D (2011) Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. [Review]. J Nutr Biochem 22(9):799–806. https://doi.org/10.1016/j.jnutbio.2010.11.001 PubMedPubMedCentral

Bao B, Ahmad A, Li Y, Azmi AS, Ali S, Banerjee S, Kong D, Sarkar FH (2012) Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opin Ther Targets 16(10):1041–1054. https://doi.org/10.1517/14728222.2012.714774 PubMed

10.

Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH (2010) Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. [Article]. Drug Resist Updat 13(4–5):109–118. https://doi.org/10.1016/j.drup.2010.07.001 PubMedPubMedCentral

11.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. [Review]. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013 PubMed

12.

Suman P, Mishra S, Chander H (2018) High expression of FBP17 in invasive breast cancer cells promotes invadopodia formation. Med Oncol 35(5):71PubMed

13.

Binayke A, Mishra S, Suman P, Das S, Chander H (2019) Awakening the "guardian of genome": reactivation of mutant p53. Cancer Chemother Pharmacol 83(1):1–15. https://doi.org/10.1007/s00280-018-3701-x PubMed

14.

Chander H, Truesdell P, Meens J, Craig AW (2013) Transducer of Cdc42-dependent actin assembly promotes breast cancer invasion and metastasis. Oncogene 32(25):3080–3090PubMed

15.

Kremerskothen J, Plaas C, Büther K, Finger I, Veltel S, Matanis T, Liedtke T, Barnekow A (2003) Characterization of KIBRA, a novel WW domain-containing protein. [Article]. Biochem Biophys Res Commun 300(4):862–867. https://doi.org/10.1016/S0006-291X(02)02945-5 PubMed

16.

Hilton HN, Stanford PM, Harris J, Oakes SR, Kaplan W, Daly RJ, Ormandy CJ (2008) KIBRA interacts with discoidin domain receptor 1 to modulate collagen-induced signalling. [Article]. Biochim Biophys Acta, Mol Cell Res 1783(3):383–393. https://doi.org/10.1016/j.bbamcr.2007.12.007 PubMed

17.

Schneider A, Huentelman M, Kremerskothen J, Duning K, Spoelgen R, Nikolich K (2010) KIBRA: a new gateway to learning and memory? [Review]. Front Aging Neurosci 2(4). https://doi.org/10.3389/neuro.24.004.2010

18.

Yoshihama Y, Chida K, Ohno S (2012) The KIBRA-aPKC connection. Commun Integr Biol 5(2):146–151. https://doi.org/10.4161/cib.18849 PubMedPubMedCentral

19.

Duning K, Schurek E-M, Schlüter M, Bayer M, Reinhardt H-C, Schwab A, Schaefer L, Benzing T, Schermer B, Saleem MA, Huber TB, Bachmann S, Kremerskothen J, Weide T, Pavenstädt H (2008) KIBRA modulates directional migration of podocytes. J Am Soc Nephrol 19(10):1891–1903. https://doi.org/10.1681/asn.2007080916 PubMedPubMedCentral

20.

Herb A, Wisden W, Catania MV, Maréchal D, Dresse A, Seeburg PH (1996) Prominent dendritic localization in forebrain neurons of a novel mRNA and its product, dendrin. [Article]. Mol Cell Neurosci 8(5):367–374. https://doi.org/10.1006/mcne.1996.0594

21.

Neuner-Jehle M, Denizot JP, Borbély AA, Mallet J (1996) Characterization and sleep deprivation-induced expression modulation of dendrin, a novel dendritic protein in rat brain neurons. J Neurosci Res 46(2):138–151. https://doi.org/10.1002/(SICI)1097-4547(19961015)46:2<138::AID-JNR2>3.0.CO;2-I PubMed

22.

Rayala SK, den Hollander P, Manavathi B, Talukder AH, Song C, Peng S, Barnekow A, Kremerskothen J, Kumar R (2006) Essential role of KIBRA in co-activator function of dynein light chain 1 in mammalian cells. J Biol Chem 281(28):19092–19099. https://doi.org/10.1074/jbc.M600021200 PubMed

23.

Ji M, Yang S, Chen Y, Xiao L, Zhang L, Dong J (2012) Phospho-regulation of KIBRA by CDK1 and CDC14 phosphatase controls cell-cycle progression. Biochem J 447(1):93–102. https://doi.org/10.1042/bj20120751 PubMed

24.

Xiao L, Chen Y, Ji M, Volle DJ, Lewis RE, Tsai M-Y, Dong J (2011) KIBRA protein phosphorylation is regulated by mitotic kinase Aurora and protein phosphatase 1. J Biol Chem 286(42):36304–36315. https://doi.org/10.1074/jbc.M111.246850 PubMedPubMedCentral

25.

Yang S, Ji M, Zhang L, Chen Y, Wennmann DO, Kremerskothen J, Dong J (2014) Phosphorylation of KIBRA by the extracellular signal-regulated kinase (ERK)–ribosomal S6 kinase (RSK) cascade modulates cell proliferation and migration. Cell Signal 26(2):343–351. https://doi.org/10.1016/j.cellsig.2013.11.012 PubMed

26.

Mavuluri J, Beesetti S, Surabhi R, Kremerskothen J, Venkatraman G, Rayala SK (2016) Phosphorylation dependent regulation of DNA damage response of adaptor protein KIBRA in cancer cells. Mol Cell Biol 36(9):1354–1365. https://doi.org/10.1128/MCB.01004-15 PubMedPubMedCentral

27.

Dobrosotskaya I, Guy RK, James GL (1997) MAGI-1, a membrane-associated guanylate kinase with a unique arrangement of protein-protein interaction domains. [Article]. J Biol Chem 272(50):31589–31597. https://doi.org/10.1074/jbc.272.50.31589 PubMed

28.

Büther K, Plaas C, Barnekow A, Kremerskothen J (2004) KIBRA is a novel substrate for protein kinase Cζ. [Article]. Biochem Biophys Res Commun 317(3):703–707. https://doi.org/10.1016/j.bbrc.2004.03.107 PubMed

29.

Rizo J, Südhof TC (1998) C2-domains, structure and function of a universal Ca2+−binding domain. J Biol Chem 273(26):15879–15882. https://doi.org/10.1074/jbc.273.26.15879 PubMed

30.

Fanning AS, Anderson JM (1999) PDZ domains: fundamental building blocks in the organization of protein complexes at the plasma membrane. J Clin Investig 103(6):767–772PubMedPubMedCentral

31.

Kremerskothen J, Plaas C, Kindler S, Frotscher M, Barnekow A (2005) Synaptopodin, a molecule involved in the formation of the dendritic spine apparatus, is a dual actin/α-actinin binding protein. J Neurochem 92(3):597–606. https://doi.org/10.1111/j.1471-4159.2004.02888.x PubMed

32.

Kremerskothen J, Kindler S, Finger I, Veltel S, Barnekow A (2006) Postsynaptic recruitment of Dendrin depends on both dendritic mRNA transport and synaptic anchoring. J Neurochem 96(6):1659–1666. https://doi.org/10.1111/j.1471-4159.2006.03679.x PubMed

33.

Lauriat TL, Dracheva S, Kremerskothen J, Duning K, Haroutunian V, Buxbaum JD, Hyde TM, Kleinman JE, Alison McInnes L (2006) Characterization of KIAA0513, a novel signaling molecule that interacts with modulators of neuroplasticity, apoptosis, and the cytoskeleton. Brain Res 1121(1):1–11. https://doi.org/10.1016/j.brainres.2006.08.099 PubMed

34.

Shin K, Straight S, Margolis B (2005) PATJ regulates tight junction formation and polarity in mammalian epithelial cells. J Cell Biol 168(5):705–711. https://doi.org/10.1083/jcb.200408064 PubMedPubMedCentral

35.

Shin K, Wang Q, Margolis B (2007) PATJ regulates directional migration of mammalian epithelial cells. EMBO Rep 8(2):158–164. https://doi.org/10.1038/sj.embor.7400890 PubMedPubMedCentral

36.

Traer CJ, Rutherford AC, Palmer KJ, Wassmer T, Oakley J, Attar N, et al. (2007) SNX4 coordinates endosomal sorting of TfnR with dynein-mediated transport into the endocytic recycling compartment. Nat Cell Biol 9(12):1370. https://doi.org/10.1038/ncb1656 PubMed

37.

Weigelt B, Peterse JL, Van't Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5(8):591–602PubMed

38.

Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massagué J (2005) Genes that mediate breast cancer metastasis to lung. Nature 436(7050):518–524PubMedPubMedCentral

39.

Bos PD, Zhang XH-F, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massagué J (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459(7249):1005–1009PubMedPubMedCentral

40.

Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6):537–549PubMed

41.

Hilton HN, Stanford PM, Harris J, Oakes SR, Kaplan W, Daly RJ, Ormandy CJ (2008) KIBRA interacts with discoidin domain receptor 1 to modulate collagen-induced signalling. Biochimica et Biophysica Acta (BBA)-Mol Cell Res 1783(3):383–393. https://doi.org/10.1016/j.bbamcr.2007.12.007

42.

Duning K, Schurek E-M, Schlüter M, Bayer M, Reinhardt H-C, Schwab A, Schaefer L, Benzing T, Schermer B, Saleem MA, Huber TB, Bachmann S, Kremerskothen J, Weide T, Pavenstädt H (2008) KIBRA modulates directional migration of podocytes. J Am Soc Nephrol: JASN 19(10):1891–1903. https://doi.org/10.1681/ASN.2007080916 PubMedPubMedCentral

43.

Barker KT, Martindale JE, Mitchell PJ, Kamalati T, Page MJ, Phippard DJ et al (1995) Expression patterns of the novel receptor-like tyrosine kinase, DDR, in human breast tumours. [Article]. Oncogene 10(3):569–575PubMed

44.

Vogel WF, Aszódi A, Alves F, Pawson T (2001) Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. [Article]. Mol Cell Biol 21(8):2906–2917. https://doi.org/10.1128/MCB.21.8.2906-2917.2001 PubMedPubMedCentral

45.

Fata JE, Werb Z, Bissell MJ (2004) Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. [Review]. Breast Cancer Res 6(1):1–11PubMed

46.

Faraci-Orf E, McFadden C, Vogel WF (2006) DDR1 signaling is essential to sustain Stat5 function during lactogenesis. J Cell Biochem 97(1):109–121. https://doi.org/10.1002/jcb.20618 PubMed

47.

Sun R, Gao P, Chen L, Ma D, Wang J, Oppenheim JJ, Zhang N (2005) Protein kinase C ζ is required for epidermal growth factor–induced chemotaxis of human breast Cancer cells. Cancer Res 65(4):1433–1441. https://doi.org/10.1158/0008-5472.can-04-1163 PubMed

48.

Wu J, Zhang B, Wu M, Li H, Niu R, Ying G, Zhang N (2010) Screening of a PKC ζ-specific kinase inhibitor PKCzI257.3 which inhibits EGF-induced breast cancer cell chemotaxis. [journal article]. Investig New Drugs 28(3):268–275. https://doi.org/10.1007/s10637-009-9242-8

49.

Zhang F, Zhang X, Li M, Chen P, Zhang B, Guo H, Cao W, Wei X, Cao X, Hao X, Zhang N (2010) mTOR complex component Rictor interacts with PKCζ and regulates Cancer cell metastasis. Cancer Res 70(22):9360–9370. https://doi.org/10.1158/0008-5472.can-10-0207 PubMed

50.

Urtreger AJ, Grossoni, VC, Falbo, KB, Kazanietz, MG, & Bal de Kier Joffe, ED (2005) Atypical protein kinase C-ζ modulates clonogenicity, motility, and secretion of proteolytic enzymes in murine mammary cells. Molecular Carcinogenesis: Published in cooperation with the University of Texas MD Anderson Cancer Center 42(1):29–39. https://doi.org/10.1002/mc.20066

51.

Curat CA, Vogel WF (2002) Discoidin domain receptor 1 controls growth and adhesion of mesangial cells. [Article]. J Am Soc Nephrol 13(11):2648–2656. https://doi.org/10.1097/01.ASN.0000032419.13208.0C PubMed

52.

Xie J, Haslam SZ (1997) Extracellular matrix regulates ovarian hormone-dependent proliferation of mouse mammary epithelial cells. [Article]. Endocrinology 138(6):2466–2473. https://doi.org/10.1210/en.138.6.2466 PubMed

53.

Paul A, Danley M, Saha B, Tawfik O, Paul S (2015) PKCζ promotes breast Cancer invasion by regulating expression of E-cadherin and zonula Occludens-1 (ZO-1) via NFκB-p65. Sci Rep 5:12520. https://doi.org/10.1038/srep12520

54.

Pfister KK, Fisher EMC, Gibbons IR, Hays TS, Holzbaur ELF, McIntosh JR, Porter ME, Schroer TA, Vaughan KT, Witman GB, King SM, Vallee RB (2005) Cytoplasmic dynein nomenclature. J Cell Biol 171(3):411–413. https://doi.org/10.1083/jcb.200508078 PubMedPubMedCentral

55.

Rayala SK, den Hollander P, Balasenthil S, Yang Z, Broaddus RR, Kumar R (2005) Functional regulation of oestrogen receptor pathway by the dynein light chain 1. EMBO Rep 6(6):538–544. https://doi.org/10.1038/sj.embor.7400417 PubMedPubMedCentral

56.

Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML (2006) The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121(2):144–158. https://doi.org/10.1016/j.clim.2006.06.010 PubMed

57.

Shin K, Fogg VC, Margolis B (2006) Tight junctions and cell polarity. Annu Rev Cell Dev Biol 22(1):207–235. https://doi.org/10.1146/annurev.cellbio.22.010305.104219 PubMed

58.

Margolis B, Borg J-P (2005) Apicobasal polarity complexes. J Cell Sci 118(22):5157–5159. https://doi.org/10.1242/jcs.02597 PubMed

59.

Knight JF, Sung VYC, Kuzmin E, Couzens AL, de Verteuil DA, Ratcliffe CDH, Coelho PP, Johnson RM, Samavarchi-Tehrani P, Gruosso T, Smith HW, Lee W, Saleh SM, Zuo D, Zhao H, Guiot MC, Davis RR, Gregg JP, Moraes C, Gingras AC, Park M (2018) KIBRA (WWC1) is a metastasis suppressor gene affected by chromosome 5q loss in triple-negative breast Cancer. Cell Rep 22(12):3191–3205. https://doi.org/10.1016/j.celrep.2018.02.095 PubMedPubMedCentral

60.

Arivazhagan L, Surabhi RP, Kanakarajan A, Sundaram S, Pitani RS, et al. (2017) KIBRA attains oncogenic activity by repressing RASSF1A. Br J Cancer 117(4):553. https://doi.org/10.1038/bjc.2017.192

Title: KIBRA Team Up with Partners to Promote Breast Cancer Metastasis
Authors: Garima Singh
Sarthak Mishra
Harish Chander
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keywords: Metastasis
Breast Cancer
Breast Cancer
Published in: Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00660-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy

Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site

CUL1 Knockdown Attenuates the Adhesion, Invasion, and Migration of Triple-Negative Breast Cancer Cells via Inhibition of Epithelial-Mesenchymal Transition

Identification and Verification of Two Novel Differentially Expressed Proteins from Non-neoplastic Mucosa and Colorectal Carcinoma Via iTRAQ Combined with Liquid Chromatography-Mass Spectrometry

Role of Peritoneal Cytology in Patients with Early Stage Colorectal Cancer

The Association between Epidermal Growth Factor Receptor Single Nucleotide Polymorphisms and Radiochemotherapy Response in Cervical Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer